Trientine Hydrochloride 250 Mg 100 Caps.

Description

Trientine Hydrochloride 250 Mg 100 Caps.

1. Clinical information

1.1 Therapeutic indications

Trientine Hydrochloride is indicated for the treatment of Wilson’s disease in adults, adolescents and children who are intolerant of D-penicillamine therapy for 5 years.

1.2 Posology and method of administration

Treatment should only be initiated by specialist physicians experienced in treating Wilson ‘s disease.

Drug amounts information

The initial dose usually corresponds to the lowest dose in the range, and the dose should then be adapted to the patient’s clinical response.

The recommended dose is between 450 mg and 975 mg (3 to 6 ½ film-coated tablets) per day in 2 to 4 divided doses.

Special populations

Old

Dose adjustment is not required in elderly patients.

Pediatric population

The initial dose in pediatrics is lower than in adults and depends on age and body weight.
Child ≥ 5 years
The dose is usually (between 1 mg and 225 per day and 600 half-divided dose 4-2 film-coated tablets 4).
Children under 5 years old
The safety and efficacy of trientin in children under 5 years of age have not been established.
The pharmaceutical form is not suitable for application to children under 5 years old.
Recommended doses of Trientine Hydrochloride are expressed as mg trientine base (i.e. not in mg of the trientin tetrahydrochloride salt).

Method of Application

Trientine Hydrochloride is for oral use. Film-coated tablets should be swallowed with water. The drawn film-coated tablet may be divided into two equal halves, if necessary, to provide a more precise dose or to facilitate administration.

It is important that Trientine Hydrochloride is given on an empty stomach, at least one hour before meals or two hours after meals and at least one hour after any other medicinal product, food or milk.

MILK SUPPLEMENT OVERSEAS DRUG PRICE LIST (ANNEX-4 / C)
Medicines marked with (**) in the column “DRUG SUPPLIED BY THE INSTITUTION” are provided by the Ankara Social Security Provincial Directorate Ibn Sina Health Social Security Center. ”
RG- 04/09 / 2019-30878 / 61-c art. Force:
1) Medicines with price change date, entry date, release date, activation date or passive date on the specified dates,
2) Drugs without price change date, entry date, activation date or passive date on 04/09/2019,
3) The drugs with the (*) mark in the reference price group and the drug name / active substance name / barcode change date will enter into force on 12/09/2019. ”